Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of epinephrine pre-filled syringe in patients with type I allergic reactions including anaphylaxis

Next Previous
Trial Profile

Efficacy of epinephrine pre-filled syringe in patients with type I allergic reactions including anaphylaxis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jun 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Epinephrine (Primary)
  • Indications Anaphylaxis; Immediate hypersensitivity
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 15 Jun 2017 According to a company media release, the US FDA has approved Adamis' epinephrine injection, USP, 1:1000 (0.3 mg Pre-filled single dose syringe) (PFS) for the emergency treatment of allergic reactions (Type I) including anaphylaxis. The FDA has also approved the PFS trade name of Symjepi.
    • 12 Apr 2016 According to an Adamis Pharmaceuticals media release, FDA agency action date (PDUFA date) for Epinephrine Pre-filled Syringe (PFS) is 4 Jun 2016.
    • 07 Dec 2015 According to a media release, Adamis Pharmaceuticals has resubmitted the NDA to the U.S. FDA for its epinephrine pre-filled syringe (PFS) for the emergency treatment of anaphylaxis.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top